Back to Search
Start Over
Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands
- Source :
- European Journal of Cancer, 72, 156-165. ELSEVIER SCI LTD, Jochems, A, Schouwenburg, M G, Leeneman, B, Franken, M G, van den Eertwegh, A J M, Haanen, J B A G, Gelderblom, H, Uyl-de Groot, C A, Aarts, M J B, van den Berkmortel, F W P J, Blokx, W A M, Cardous-Ubbink, M C, Groenewegen, G, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Koornstra, R H, Kruit, W H, Louwman, M W, Piersma, D, van Rijn, R S, Ten Tije, A J, Vreugdenhil, G, Wouters, M W J M & van der Hoeven, J J M 2016, ' Dutch Melanoma Treatment Registry : Quality assurance in the care of patients with metastatic melanoma in the Netherlands ', European Journal of Cancer, vol. 72, pp. 156-165 . https://doi.org/10.1016/j.ejca.2016.11.021, European Journal of Cancer, 72, 156-165, European Journal of Cancer, 72, 156. Elsevier Limited, European Journal of Cancer, 72, 156-165. Elsevier Ltd., European Journal of Cancer, 72, pp. 156-165, European Journal of Cancer, 72, 156-165. Pergamon
- Publication Year :
- 2017
- Publisher :
- Elsevier Ltd., 2017.
-
Abstract
- Contains fulltext : 174807.pdf (Publisher’s version ) (Closed access) BACKGROUND: In recent years, the treatment of metastatic melanoma has changed dramatically due to the development of immune checkpoint and mitogen-activated protein (MAP) kinase inhibitors. A population-based registry, the Dutch Melanoma Treatment Registry (DMTR), was set up in July 2013 to assure the safety and quality of melanoma care in the Netherlands. This article describes the design and objectives of the DMTR and presents some results of the first 2 years of registration. METHODS: The DMTR documents detailed information on all Dutch patients with unresectable stage IIIc or IV melanoma. This includes tumour and patient characteristics, treatment patterns, clinical outcomes, quality of life, healthcare utilisation, informal care and productivity losses. These data are used for clinical auditing, increasing the transparency of melanoma care, providing insights into real-world cost-effectiveness and creating a platform for research. RESULTS: Within 1 year, all melanoma centres were participating in the DMTR. The quality performance indicators demonstrated that the BRAF inhibitors and ipilimumab have been safely introduced in the Netherlands with toxicity rates that were consistent with the phase III trials conducted. The median overall survival of patients treated with systemic therapy was 10.1 months (95% confidence interval [CI] 9.1-11.1) in the first registration year and 12.7 months (95% CI 11.6-13.7) in the second year. CONCLUSION: The DMTR is the first comprehensive multipurpose nationwide registry and its collaboration with all stakeholders involved in melanoma care reflects an integrative view of cancer management. In future, the DMTR will provide insights into challenging questions regarding the definition of possible subsets of patients who benefit most from the new drugs.
- Subjects :
- Male
INDICATORS
Cancer Research
Skin Neoplasms
Quality Assurance, Health Care
Cost-Benefit Analysis
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
Population-based
Systemic therapy
VEMURAFENIB
Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2]
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Health care
Registries
030212 general & internal medicine
Vemurafenib
Melanoma
MUTATION
Netherlands
education.field_of_study
Middle Aged
OPEN-LABEL
CANCER
Quality assurance
Women's cancers Radboud Institute for Health Sciences [Radboudumc 17]
Oncology
030220 oncology & carcinogenesis
SAFETY
SURVIVAL
Female
Checkpoint inhibitors
medicine.drug
Adult
medicine.medical_specialty
Registry
Population
Ipilimumab
Cancer Care Facilities
Metastatic melanoma
03 medical and health sciences
Quality of life (healthcare)
Journal Article
medicine
Humans
Intensive care medicine
education
Protein Kinase Inhibitors
Aged
Quality of Health Care
Clinical Audit
business.industry
IPILIMUMAB
Cancer
medicine.disease
Survival Analysis
Surgery
MAP kinase inhibitors
Quality of Life
business
FOLLOW-UP
Subjects
Details
- ISSN :
- 18790852 and 09598049
- Volume :
- 72
- Database :
- OpenAIRE
- Journal :
- European Journal of Cancer
- Accession number :
- edsair.doi.dedup.....1864b94a331d5ff1d6b8ce06aeb92b04